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1. Introduction 
Regarding the definition of gliomatosis cerebri (hereinafter referred to as "GC"), the 3rd 
edition of the WHO Classification of Central Nervous System Tumors (hereinafter referred 
to as "3rd ed.") provides only a five-line description that GC is a diffuse, frequently bilateral, 
glioma that infiltrates the brain, involving more than two lobes. It often extends to the 
infratentorial structures and even to the spinal cord. Compared with this, the definition in 
its 4th edition (hereinafter referred to as "4th ed.") is described in 13 lines, stating that GC 
involves at least 3 lobes and is usually bilateral, extending from the cerebral white matter, 
including the deep and subcortical portions, and often infiltrating the brain stem and the 
spinal cord. In the 4th ed., GC is characterized by a widespread infiltration of the brain by 
tumor, occurring as bilateral lesions involving commissural fibers, and frequently 
infiltrating from the brain stem to the spinal cord. Moreover, the 4th ed. states that GC is 
mainly astrocytic tumor but, in some cases, mainly consists of oligodendroglial tumor cells 
(Akimoto, 2004; Balko, 1996; Levin, 2004; Sanson, 2004, Taillibert, 2006). Unlike the 3rd ed., 
which specifies the histological malignancy as Grade III, the 4th ed. rates it basically as 
Grade III, without specifying it, although recognizing the importance of the evaluation of 
histological malignancy, in consideration of the possibility that the grade may be 
underestimated in some cases due to tissue sampling problems (Akimoto, 2004; Nishioka, 
1996). These changes in the description of the definition in the WHO Classification have 
reflected the findings of many clinicopathological researches on GC. 
This situation requires us neuro-oncologists to diagnose GC before operation and to provide 
appropriate treatment. In that sense, it is important to evaluate the extent of tumor 
progression by imaging diagnosis, mainly using MRI, and to perform adequate tissue 
sampling to enable accurate histopathological diagnosis, in accordance with the 4th ed. 
(Akimoto et al., 2004). In addition, it is important to establish a treatment protocol mainly 
consisting of adjunctive therapy. 
2. Clinical cases (Table 1) 
We have encountered 8 cases in which GC was suspected based on the neuroradiological 
definition of the 4th ed. and was diagnosed pathologically. These cases aged 46 to 73 years 
(median age: 55.5 years) consisted of 3 men and 5 women. The initial symptoms were 
mainly cognitive impairment and seizure. The symptoms of ordinary brain tumor, 
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including increased intracranial pressure, as well as focal signs, including hemiparesis, 
were less frequent. The tumoral topography based on CT or MRI revealed that most of the 
lesions were diffused in the white matter, often extending to the basal ganglia, brain stem 
or cerebellum which is unlikely to be invaded by ordinary diffuse glioma. These lesions 
were characterized by bilateral progression accompanied by hypertrophy of the corpus 
callosum. Wide resection of tissue, including areas over the white matter and cortical 
regions, was considered preferable as the surgical procedure to obtain a reliable 
pathological diagnosis. Therefore, anterior temporal lobectomy and maximally possible 
tumor resection were performed. Pathological diagnosis was anaplastic astrocytoma 
(Grade III) in most of the cases. However, GC consisting of oligodendroglial tumor cells 
was found in 2 cases. Basic treatment was radiation therapy (30 Gy to whole brain and 30 
Gy focal boost) combined with chemotherapy (ACNU, Temozolomide). Except for a 
patient who developed central brain herniation in the early phase after operation, patients 
receiving sufficient adjunctive therapy tended to maintain partial response or stable 
disease. 
2.1 Case 2 
A 46-year old woman. She was admitted with a 2-month history of clumsiness and 
numbness of the right hand as well as gradual development of disorientation and right 
hemiparesis. The head MRI on admission revealed a lesion arising primarily in the left 
corona radiata and extending to the right parietal lobe and frontal lobe white matter 
through the corpus callosum, showing no obvious contrast enhancement (Fig. 1 A-D). 
CT-guided stereotactic biopsy of the left frontal lobe white matter was performed to 
make a definite diagnosis. Infiltration of large cells with abundant cytoplasm and thick 
processes, suggestive of reactive astrocytes, was observed in the matrix of the edematous 
white matter. However, a diagnosis of neoplastic lesion was not reached. Triggered by 
status epileptics, her condition deteriorated. Two months after the operation, she died of 
brain herniation. Cerebral autopsy revealed a widespread edema over the region from 
the left corona radiata to the basal ganglia, further extending to the right frontal lobe and 
the temporal lobe white matter through the corpus callosum. KB staining, Bodian 
staining, Holtzer staining, etc. demonstrated the extent of the lesion (Fig. 2 A-D). The 
pathological features of each section showed infiltration of gemistocytic cells, forming 
parallel rows along the nerve fibers. Although lack of nuclear atypism was noted, most 
of the nuclei were MIB-1 positive. The degree of myelin destruction varied across 
sections, being the most severe in the corpus callosum. However, Bodian staining 
demonstrated that the involved axis cylinder was preserved even in the corpus callosum. 
(Fig. 2 E, F) The autopsy-based diagnosis was GC consisting of gemistocytic astrocytoma. 
2.2 Case 8 
A 47-year old women. She was admitted to the hospital because of having abrupt cognitive 
impairment 1 month previously and gradual development of ataxic gait and urinary 
incontinence thereafter. Head MRI showed a lesion with enlargement of the corpus 
callosum in the white matter of the bilateral frontal lobe. Although the lesion extended from 
the bilateral corona radiata to the white matter of the parietal lobe, no obvious contrast 
enhancement was observed (Fig. 3 A-D). The partial removal of the tumor was performed to  
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Case Age/Sex 
Initial 
symptom 
Tumoral 
Topography
Surgery Pathological Dx Treatment 
Prognosi
s 
1 
54/ 
Male 
Headache, 
Depression 
White 
matter,       
Basal 
ganglia,      
Brain Stem, 
Cerebellum
ATL 
Anaplastic 
oligodendroglioma
RTx 
D: 2 
months 
2 
46/ 
Female 
Disorientation, 
Heminumbne
ss 
White 
matter,       
Basal 
ganglia,      
Corpus 
callosum 
Biopsy 
Gemistocytic 
astrocytoma 
None 
D: 2 
weeks 
3 
71/ 
Female 
Seizure, 
Hemiparesis
White 
matter,       
Corpus 
callosum 
Partial 
removal
Glioblastoma none 
D: 8 
months 
4 
50/ 
Female 
Seizure,  
Cognitive 
impairment
White 
matter, Basal 
ganglia 
Biopsy 
Anaplastic 
astrocytoma 
RTx, 
Chemo Tx 
D: 26 
months 
5 
66/ 
Male 
Cognitive 
impairment
White 
matter,       
Corpus 
callosum 
Biopsy 
Anaplastic 
astrocytoma 
RTx, 
Chemo Tx 
A: 49 
months 
6 
73/ 
Male 
Seizure 
White 
matter,       
Basal ganglia
ATL 
Anaplastic 
astrocytoma 
RTx, 
Chemo Tx 
D: 4 
months 
7 
57/ 
Female 
Cognitive 
impairment
White 
matter,       
Basal ganglia
ATL 
Anapalstic 
astrocytoma 
RTx, 
Chemo Tx 
D: 20 
months 
8 
47/ 
Female 
Cognitive 
impairment
White 
matter,       
Corpus 
callosum 
Partial 
removal
Anaplastic 
oligodendroglio
ma 
RTx, 
Chemo Tx 
A: 11 
months 
ATL: anterior temporal lobectomy, RTx: radiation therapy, Chemo Tx: chemotherapy, D: dead, A: alive 
Table 1. Case summary 
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(a)     (b) 
 
 
 
 
 
(c)     (d) 
T2-weighted MRI (A, B) demonstrated diffuse high intensity in the white matter of both cerebral 
hemispheres, with enlargement of the corpus callosum. T1-weighted MRI with Gd-DTPA (C, D) 
demonstrated slightly low intensity in the white matter without enhancement. 
Fig. 1. MRI on admission (A-D) 
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f 
Klüver-Barrera stain (A) demonstrated the affected region to be a broad region of myelin destruction 
extending from the white matter of the left parietal lobe to the basal ganglia and to the corpus callosum 
and in a part of the right hemisphere. Bodian stain (B) demonstrated the preservation of axons, but the 
intensity of staining of the white matter and corpus callosum was slightly decreased owing to 
edematous change. Holzer stain (C) demonstrated the broad area of reactive gliosis. The region showed 
increased atypical gemistocyte-like cells of various sizes and forms [D: hematoxylin and eosin (HE) 
stain, ×100], Immunohistochemically, most tumor cells were positive for GFAP (E). Klüver-Barrera stain 
(F) showed extensive destruction of myelin. 
Fig. 2. Coronal section of the autopsy brain (A-C) and microscopic appearance of autopsy 
material (D-F) 
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(a)     (b) 
 
 
(c)     (d) 
FLAIR MRI (A, B) demonstrated diffuse high intensity in the white matter of both frontal lobe and 
bilateral corona radiata, with enlargement of the corpus callosum. T1-weighted with Gd-DTPA (C, D) 
demonstrated low intensity in the white matter of the left frontal lobe without enhancement. 
Fig. 3. MRI on admission (A-D) 
make a definite diagnosis showed a dense proliferation of tumor cells with round nuclei, 
scant cytoplasm and perinuclear halo in the left superior frontal gyrus. The perineuronal 
satellitosis-like infiltration of tumor cells was observed even in the deep layer of the 
cerebral cortex. Myelin was preserved although partially destroyed by tumor cell 
infiltration (Fig. 4 A, B). The tumor cells were found to be Olig-2 positive, and the 
proportion of MIB-1 positive patients was also high. As a result of analysis using 
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fluorescence in situ hybridization (FISH), she was found to be positive for 1pLOH (1p36) 
and 19qLOH (19q36) (Fig. 4 C, D). Based on these results, she was diagnosed with GC 
consisting of anaplastic oligodendroglioma cells. After the operation, she underwent 
radiation therapy (60 Gy) combined with chemotherapy using oral temozolomide. At 11 
months post-operative, a reduction in the lesion size was observed, with an improvement 
in cognitive function. 
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The region showed increased atypical oligodendroglial cells of various sizes and forms  
(A: HE stain, ×100). Luxol fast blue and HE stain showed extensive destruction of myelin  
(B, ×100). Immunohistochemically, most tumor cells were positive for olig2 (C) and MIB-1 (D). 
Fig. 4. Microscopic appearance of resected tissue (A-D) 
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3. Discussion 
3.1 Points to be noted in radiological diagnosis 
Based on the definition of the 4th ed., confirmation of the presence of bilateral lesions over 
at least 3 lobes as well as the absence of an obvious focal tumor mass is considered essential 
to make an imaging-based diagnosis of GC. In addition, detection of infiltration of the basal 
ganglia, brain stem, cerebellum and spinal cord lends more confidence to the imaging-based 
diagnosis of GC. In other words, GC is considered a pathological condition where great 
emphasis is placed only on the invasive potential among the two growth mechanisms of 
ordinary glioma, i.e., the proliferative potential and invasive potential (Akimoto, 2004; 
Peretti-Viton, 2002; Saraf-Lavi, 2003). According to one report (Sanson et al., 2004), factors 
determining the diagnosis of GC based on MRI are: (1) a high signal area over at least 3 
lobes on T2-weighted and FLAIR images; (2) absence of a contrast-enhanced tumor mass of 
1 cm or greater; and (3) thickening of the corpus callosum or anterior commissure. These 
factors are the criteria adopted in the 4th ed. Such a clear definition may make it possible to 
suspect the presence of GC by performing MRI. However, these imaging findings are also 
obtained in white matter lesions other than tumors, such as demyelinating disease, 
encephalitis and venous sinus thrombosis (Essig, 2001; Saraf-Lavi, 2003). Therefore, it 
becomes necessary to confirm the presence of tumor cells by histological diagnosis. In recent 
years, studies evaluating GC by MR spectroscopy have been published (Bendszus, 2000; 
Galanaud, 2003; Saraf-Lavi, 2003). According to these studies, increased choline and 
decreased NAA levels, which are findings characteristic of glioma, are not necessarily 
observed in GC, but rather increased NAA levels are often observed. Increased myoinositol 
(m-Ins), which indicates increased activity of glia cells, has been reported as a finding 
characteristic of GC. Although the 4th ed. only states that multivoxel MRS is useful for 
determining the target of biopsy, it appears that biopsy of the sites with increased choline or 
m-Ins levels lends more confidence to the histological diagnosis of GC. 
3.2 Points to be noted in pathological diagnosis 
It is important to be faithful to the criteria for the pathological diagnosis of GC (Scheinker & 
Evans, 1943). More specifically, GC is basically defined as an invasive and tumoral lesion, 
with no tumor mass centered in the white matter, and the axis cylinder is preserved even 
when myelin destruction takes place (Akimoto, 2004; Peretto-Viton, 2002; Vates, 2003). To 
thoroughly carry out these evaluations, stereotactic biopsy sampling is often difficult. We 
previously reported the need to remove, as much as possible, the cerebral lobes with lesions 
detectable by imaging (Akimoto, 2004). In other words, not only the evaluation of tumor 
cells but also the evaluation of normal tissue is necessary for making the pathological 
diagnosis of GC. The cases presented in this article demonstrate the significance of the 
additional response evaluation for myelin by KB staining, axis cylinder by Bodian staining 
and reactive glia by Holtzer staining. The evaluation of tumor cells infiltrating between 
normal nerve fibers is by no means easy. In addition, the shape of the nuclei varies greatly 
from elongated-form or fusiform to round-form, and no consistency is found regarding the 
presence or absence of atypical cells. In fact, there are some reports on cases of GC 
consisting of oligodendroglioma-like cells, as shown in Case 8 (Akimoto, 2004; Balko, 1996; 
Benjelloun, 2001; Sanson, 2004; Vates, 2003). Confirmation of the preservation of the axonal 
structure after evaluation of the proliferative potential of infiltrating cells by MIB-1 and 
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AgNORs can contribute to the diagnosis of GC (Akimoto, 2004). In the 4th ed., the range of 
MIB-1 index is specified to be from not more than 1% to 30%, which is difficult to 
understand. However, it is also the fact that objective calculation of MIB-1 index is 
extremely difficult in tissues containing responsive glia cells due to normal tissue infiltration 
(Akimoto, 2004; Nishioka, 1996; Vates, 2003). Therefore, we consider it useful to evaluate the 
proliferative potential of each cell by AgNORs. However, there have only been two case 
reports on AgNORs in GC(Hara et al., 1991). A recent study has reported that L1, which is a 
cell adhesion factor, is expressed more abundantly in GC than in ordinary glioma (Suzuki et 
al., 2010). Since L1 is a glycoprotein that plays an important role in the migration of the 
immature neurons in the development stage, L1 might be significantly involved in the 
invasive potential of GC. In addition, it was reported that the control of L1-functions might 
contribute to the treatment of GC. Moreover, according to a study (Seiz et al., 2005) 
evaluating the mutation of IDH1 in GC, the frequency of IDH1 mutations is relatively high 
in the secondary GC, caused by the progression of diffuse astrocytoma, whereas no IDH1 
mutation was observed in primary GC. This suggests the possibility that the evaluation of 
IDH1 mutations may become important for making the diagnosis of GC, as suggested in the 
molecular analysis of the development of glioblastoma. 
3.3 Topics regarding treatment 
According to the 3rd ed., GC has extremely poor prognosis, and 1-, 2- and 3-year survival 
rates are 48%, 37% and 27%, respectively, being similar to those in glioblastoma. The 3rd 
ed. specifies only MIB-1 as a prognostic factor. However, the 4th ed. is not intended to 
provide data, and states only that age, performance status and histological features, 
especially for grade and subtype (oligodendroglioma), are important as prognostic 
factors. The deletion of the description on MIB-1 suggests the difficulty of the evaluation 
(Akimoto, 2004; Nishioka, 1996; Vates, 2003). There are many reports discussing the 
extremely poor prognosis of GC (Taillibert, 2006; Vates, 2003). However, recent studies 
have reported some cases with relatively better prognosis due to greater sensitivity to 
adjuvant therapy (Levin, 2004; Sanson, 2004; Taillibert, 2006). Of these, one report 
(Taillibert et al., 2006) summarizing 296 cases from the literature showed that the overall 
survival (OS) in GC was 14.5 months. Examined for each prognostic factor, OS was 27 
months and 9 months in KPS of ≥80 and ≤80, respectively, and 20 months and 8.5 months 
in Grade 2 and 4, respectively, showing significant differences. However, no significant 
difference was observed between cases with and without radiation therapy, and there was 
a trend for prolonged OS in patients receiving additional chemotherapy. The most 
noteworthy was the difference between cases of astrocytic tumor and oligodendroglial 
tumor: the OS was 11 months for the former and 36 months for the latter, showing a 
marked difference. Moreover, one study reported (Levin et al., 2004) that, in the use of 
temozolomide (TMZ), which is regarded as the standard treatment for ordinary glioma, 
the response rate was 45%, the median TTP to time to progression (TTP) was 13 months, 
with 1- and 2-year progression-free survival (PFS) rates of 55% and 23%, respectively. In 
another study (Sanson et al., 2004) where PCV and TMZ were used as first-line treatment 
in the 63 cases they encountered, no significant difference was observed in the response 
rate between the two treatment groups. In the study, no significant differences were 
observed in PFS and OS between patients stratified by age, tumor grade, KPS, etc. 
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However, in GC consisting of oligodendroglial tumor cells, significantly better responses 
were observed in both PFS and OS, with PFS of 21.2 months and OS of 33.9 months. 
Therefore, also for the treatment of GC, it is considered important to determine 1p, 
19qLOH and the methylation status of MGMT by adequate tissue sampling in GC, for 
additional evaluation of the sensitivity to chemotherapy. 
4. Conclusion 
In terms of diagnosis, we are focusing on the application of chemical shift imaging MR 
spectroscopy with m-Ins, application of in vivo imaging technique using L1 and integrin as 
markers, and accurate detection of oligodendroglial GC by adequate tissue sampling and 
detailed evaluations of pathological morphology and gene mutations. In terms of treatment, 
focus is being placed on the evaluation of sensitivity to chemotherapy and the establishment 
of a treatment protocol for TMZ. The algorithm from the diagnosis of GC to treatment, we 
propose currently, is shown in Table 2. The pathological conditions for the diagnosis of GC 
have been specified in the 4th ed., but GC is still stated as an orphan disease. We believe that 
a multicenter study on the treatment of patients definitely diagnosed as having GC should 
be started. 
 
 
 
Table 2. Proposed algorithm of the management of gliomatosis cerebri 
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